SCG Lima
YOU?
Author Swipe
View article: PARP AND PARG INHIBITION SELECTIVELY IMPAIR METABOLISM OF B-ALL CELL LINES AND INDUCE CYTOTOXICITY THROUGH DISTINCT CELL-DEATH PATHWAYS
PARP AND PARG INHIBITION SELECTIVELY IMPAIR METABOLISM OF B-ALL CELL LINES AND INDUCE CYTOTOXICITY THROUGH DISTINCT CELL-DEATH PATHWAYS Open
Background: Adult patients afflicted with Acute Lymphoblastic Leukemia (ALL) still represent a subset of poor prognosis, with a 5-year overall survival of around 46%. The development of new therapeutic approaches is of utmost importance to…
View article: EMPOWERING CAR-T CELL THERAPY: GITRL COSTIMULATION FOR ENHANCED ANTITUMOR RESPONSE AND IMMUNOSSUPPRESSION RESISTANCE IN SOLID TUMORS
EMPOWERING CAR-T CELL THERAPY: GITRL COSTIMULATION FOR ENHANCED ANTITUMOR RESPONSE AND IMMUNOSSUPPRESSION RESISTANCE IN SOLID TUMORS Open
The treatment of solid tumors with CAR-T cells is challenging due to the complex tumor microenvironment that impairs infiltration and persistence of injected cells. Thus, enhancing persistence and resistance to exhaustion of CAR-T cells is…
View article: PRODUCTION OF “UNIVERSAL” CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS THROUGH A HIGHLY EFFICIENT CRISPR/CAS9-INDUCED KNOCKOUT OF THE ENDOGENOUS TRAC GENE
PRODUCTION OF “UNIVERSAL” CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS THROUGH A HIGHLY EFFICIENT CRISPR/CAS9-INDUCED KNOCKOUT OF THE ENDOGENOUS TRAC GENE Open
Allogeneic Chimeric Antigen Receptor (CAR) T cell therapy represents a promising approach to overcome the accessibility limitations of conventional autologous treatment. Some advantages of such allogeneic therapy include the availability o…
View article: EXPRESSION PROFILE OF MOLECULAR CIRCADIAN CLOCK GENES PREDICTS RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA
EXPRESSION PROFILE OF MOLECULAR CIRCADIAN CLOCK GENES PREDICTS RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA Open
Objectives: Acute Myeloid Leukemia (AML) is a complex and heterogeneous disease characterized by the blockage of blood cell maturation, leading to uncontrolled proliferation of immature malignant cells. Based on cytogenetic characteristics…
View article: GENETICALLY ENGINEERED T CELLS EXPRESSING HIGH AFFINITY TCR ANTI-NY-ESO-1:HLA-A*02 ARE ABLE TO CONTROL SOLID TUMOR GROWTH IN VIVO
GENETICALLY ENGINEERED T CELLS EXPRESSING HIGH AFFINITY TCR ANTI-NY-ESO-1:HLA-A*02 ARE ABLE TO CONTROL SOLID TUMOR GROWTH IN VIVO Open
Despite the remarkable success in the use of T cells expressing Chimeric Antigen Receptors (CAR) for hematologic malignances, their application to solid tumors, which represents the majority of neoplasms, remains challenging. However, T ly…
View article: CHARACTERIZATION OF A NOVEL ANTI-CD19 CAR CONSTRUCT CO-EXPRESSING THE COSTIMULATORY MOLECULE GITRL
CHARACTERIZATION OF A NOVEL ANTI-CD19 CAR CONSTRUCT CO-EXPRESSING THE COSTIMULATORY MOLECULE GITRL Open
Adoptive therapy using Chimeric Antigen Receptor T-cell (CAR-T) technology has emerged as a groundbreaking immunotherapeutic approach for treating various hematological malignancies. Among the diverse CAR-T targets, CD19, a B-cell surface …
View article: ALL-IN-ONE VIRUS-FREE MANUFACTURING PROCESS OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS USING CRISPR/CAS9
ALL-IN-ONE VIRUS-FREE MANUFACTURING PROCESS OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS USING CRISPR/CAS9 Open
Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising therapeutic opportunity against blood cancers, leading to the six FDA-approved CAR T cell products. All commercially available products are produced following an aut…
View article: GENERATION OF T LYMPHOCYTES EXPRESSING ENGINEERED T CELL RECEPTOR TARGETING THE NY-ESO-1 TUMOR ANTIGEN USING A NEW GENETIC CONSTRUCT
GENERATION OF T LYMPHOCYTES EXPRESSING ENGINEERED T CELL RECEPTOR TARGETING THE NY-ESO-1 TUMOR ANTIGEN USING A NEW GENETIC CONSTRUCT Open
Immunotherapy based on the adoptive transfer of genetically modified T lymphocytes for the expression of engineered receptors has provided impressive results for hematological neoplasms. This is the case of T cells modified to express chim…
View article: OPTIMIZED PROTOCOLS OF EXPANSION OF PERIPHERAL BLOOD-DERIVED δT-CELLS FOR THE ESTABLISHMENT OF AN OFF-THE-SHELF ADVANCED CELL THERAPY AGAINST CANCER
OPTIMIZED PROTOCOLS OF EXPANSION OF PERIPHERAL BLOOD-DERIVED δT-CELLS FOR THE ESTABLISHMENT OF AN OFF-THE-SHELF ADVANCED CELL THERAPY AGAINST CANCER Open
The use of autologous T cells expressing chimeric antigen receptors (CAR) has revolutionized the treatment of hematological malignancies. However, the use of allogeneic CAR-T cells offers many advantages over autologous therapies, includin…
View article: ESTABLISHMENT OF A CRISPR/CAS9-BASED GENOME EDITING PLATFORM FOR THE GENERATION OF AN OFF-THE-SHELF ALLOGENEIC CAR-T CELL MODEL
ESTABLISHMENT OF A CRISPR/CAS9-BASED GENOME EDITING PLATFORM FOR THE GENERATION OF AN OFF-THE-SHELF ALLOGENEIC CAR-T CELL MODEL Open
Introduction: Chimeric antigen receptor (CAR)-T cell therapy has a remarkable clinical success. However, its autologous nature reduces accessibility to the therapy. Thus, one of the next frontiers in the field is to develop an allogeneic, …
View article: POLARIZAÇÃO DE LINFÓCITOS T AO FENÓTIPO T HELPER/CITOTÓXICO 17 PARA USO EM TERAPIAS CELULARES AVANÇADAS
POLARIZAÇÃO DE LINFÓCITOS T AO FENÓTIPO T HELPER/CITOTÓXICO 17 PARA USO EM TERAPIAS CELULARES AVANÇADAS Open
Introdução: O tratamento com linfócitos T expressando receptores quiméricos de antígeno (CAR) ou receptores de células T (TCR) artificiais tem resultado em taxas de remissão impressionantes para algumas neoplasias hematológicas. Porém, a e…